LifeCell International
LifeCell International is India's first and largest stem cell bank, headquartered in Chennai, offering community umbilical cord blood banking, a 4,000+ test diagnostic lab network, placental-tissue biologics, hospital lab management services, and the AreoVeda natural skincare brand, serving 4.5 lakh+ families across India.
- Company typePrivate
- Founded2004
- HeadquartersChennai, India
- Headcount1,001–5,000
- GTM typeB2B and B2C
- OfferingServices
What LifeCell International does
LifeCell International Private Limited, founded in 2004 in Chennai, is India's first commercial umbilical cord blood stem cell bank, having licensed technology from CryoCell International (USA). The company has built a diversified healthcare platform anchored by community stem cell banking: under the BabyCord brand, it offers 1-year, 21-year, and 75-year storage plans at INR 20,330 / INR 49,144 / INR 63,551 respectively, tested against 19 parameters, with each subscriber gaining access to a 75,000+ unit shared community inventory that delivers a >97% probability of finding an Indian-origin stem cell match. Underlying technology includes Pentastarch-based cord blood processing (99% red blood cell removal), vapour-phase liquid nitrogen cryopreservation with continuous monitoring and solar-backed energy at twin facilities in Chennai and Jhajjar, and AABB/AATB/CAP/NABL-ISO 15189 accredited operations. The company operates 30+ regional diagnostic laboratories and 500+ collection centres across 2,500+ Indian cities, offering 4,000+ tests from routine health checkups (Ayushman Basic/Total/Vital packages) to oncology, reprogenomics and IVF under the LifeCell Diagnostics brand.
LifeCell monetizes across five revenue streams: subscription stem cell banking (with multi-year contracts and EMI financing through Bajaj Finserv, Pinelabs, Axio, and LiquiLoans), per-test diagnostic services with home sample collection, sale of placental-tissue allograft wound-care products (HuPla FLO, HuPla Matrix, HuPla PHMB) via the Cellution Biologics subsidiary, the AreoVeda natural skincare line for mothers and babies launched in 2024, and B2B hospital lab management contracts covering end-to-end lab setup, operations and accreditation support (including a partnership with the MFine digital health platform). Go-to-market is hybrid: direct-to-consumer online booking and digital marketing target expectant parents and diagnostic consumers, while enterprise field sales target hospitals for lab outsourcing. Subsidiary brands include AreoVeda (wholly-owned natural skincare) and Cellution Biologics (wholly-owned biologics), with corporate restructuring underway via a February 2025 tribunal-approved merger scheme involving CBPL, LifeWell, HS Path and Novocura. The company has cumulatively served 4,50,000+ families, executed 64 Indian and 19 international stem cell retrievals, and remains privately held, having raised capital from Brand Capital (2007), Helion Venture Partners (~$6.4M, 2013), and OrbiMed (~$34.5M, 2021).
LifeCell International firmographics
Firmographics- Name
- LifeCell International
- Legal name
- LifeCell International Private Limited
- Website
- https://lifecell.in
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- LifeCell International is India's first and largest stem cell bank, headquartered in Chennai, offering community umbilical cord blood banking, a 4,000+ test diagnostic lab network, placental-tissue biologics, hospital lab management services, and the AreoVeda natural skincare brand, serving 4.5 lakh+ families across India.
- Ownership category
- akta.pro rank
LifeCell International industry classification
Industry- Product category
- Stem Cell Banking
- NAICS
- Blood and Organ Banks (621991), Medical and Diagnostic Laboratories (6215), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
Keywords
Where LifeCell International is headquartered
LocationHeadquarters
- HQ city
- Chennai
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
LifeCell International business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Stem Cell Banking Services: Annual subscription-based stem cell banking with multiple plan durations (1 year, 21 years, 75 years). Customers pay upfront or through EMI financing. Revenue includes processing fees, storage fees, and optional medical insurance top-ups.
- Diagnostic/Lab Testing Services: Per-test and package-based diagnostic services covering routine to advanced tests including genetic testing, cancer screening, and reproductive health. Home sample collection available.
- Allograft/Biologics Products: Sale of biological wound care products derived from human placenta and umbilical cord tissues, including HuPla FLO, HuPla Matrix, and HuPla PHMB.
- Skincare Products (AreoVeda): Sale of skincare products for pregnant women, new mothers, and babies. First natural baby skincare range with ceramides to receive Ecocert certification.
- Hospital Lab Management Services: B2B services offering hospitals complete lab setup, management, and optimization. Revenue generated through service contracts with healthcare facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | BabyCord 1 Year Plan - Annual stem cell banking |
| Subscription | Multi-year contract | BabyCord 21 Years Plan - Medium-term storage |
| Subscription | Multi-year contract | BabyCord 75 Years Plan - Long-term preservation |
| Unit Pricing | Pay-as-you-go | Ayushman Basic Package |
| Unit Pricing | Pay-as-you-go | Ayushman Total Package |
| Unit Pricing | Pay-as-you-go | Ayushman Vital Package |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
LifeCell International product offering
Product offeringCore offering
LifeCell International operates a community stem cell banking service that preserves umbilical cord blood stem cells for expectant parents and their families, with subscription-based plans ranging from 1-year to 75-year storage. The company also provides pan-India diagnostic laboratory services (4,000+ tests through LifeCell Diagnostics), placental tissue-derived wound care allograft products (HuPla FLO, HuPla Matrix, HuPla PHMB), B2B hospital lab management services, and the AreoVeda natural skincare brand for mothers and babies.
Product overview
LifeCell International operates a diversified healthcare ecosystem with three core business segments: (1) Community Stem Cell Banking (BabyCord) offering cord blood preservation with 1-year, 21-year, and 75-year storage plans with family coverage and access to 75,000+ cord blood units; (2) LifeCell Diagnostics providing 4000+ laboratory tests including Ayushman health checkup packages (Basic, Total, Vital) and specialized oncology/reprogenomics testing; (3) Health Clinic (Allografts) offering placental tissue-derived wound care products (HuPla FLO, Matrix, PHMB). The company also launched AreoVeda skincare brand in 2024 for mothers and babies, and provides hospital lab management services.
Differentiator
Problem solved
Functional benefit
Brands
- AreoVeda: India's first natural baby skincare range with ceramides to receive Ecocert certification, using lab-grown human skin cell models for testing and formulations containing more than 98% natural ingredients.
- Cellution Biologics
- BabyCord
- StemMatch
- MFine
Quantifiable outcome
- >97% chance of finding suitable Indian-origin stem cell match
- +4 more outcomes
Companies that use LifeCell International
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
LifeCell International technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
LifeCell International partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and supporting.
- CryoCell International, USAcoreLicensed technology from CryoCell International, USA (world's first stem cell bank with 27+ years of experience) to establish India's first stem cell bank in 2004. This partnership enabled LifeCell to bring cord blood banking technology to the Indian market.
- MFinesupportingDigital health platform partnership driving access and engagement through corporate health checkups and increased patient walk-ins.
Scale indicators13 records
Recent moves6 records
Expansion highlights7 records
LifeCell International competitors and assessment
Company assessmentDirect peers
- Mamaearth (Honasa Consumer): India's leading D2C natural baby and maternal skincare brand. Directly competes with AreoVeda on natural, dermatologically-tested skincare for mothers and babies across e-commerce and offline retail channels.
- Metropolis Healthcare: India's second-largest diagnostic chain operating NABL-accredited labs across India. Directly competes with LifeCell Diagnostics on routine and advanced testing, B2B hospital partnerships, and home sample collection services.
- Thyrocare Technologies: Preventive healthcare-focused diagnostic chain offering affordable health checkup packages directly competing with LifeCell's Ayushman packages. Operates B2B hospital partnerships and home sample collection nationwide.
- CordLife India: Direct competitor in Indian cord blood banking market. Both target expectant parents with private and community banking models and similar storage plans. Directly competes for the same Indian middle-class consumer segment with comparable AABB accreditation.
- ReeLabs: India-based stem cell banking and processing company with private cord blood banking offering and stem cell therapy services. Directly competes with LifeCell on stem cell banking and processing services for Indian customers.
- StemCyte India: US-headquartered cord blood bank with India presence. Competes with LifeCell in private and public banking, particularly leveraging dual inventory from domestic and international cord blood units for higher match probability.
- CryoSave (now BioSave): European-origin stem cell bank with India operations. Offers private and family cord blood banking services directly competing with LifeCell on storage plans, accreditation standards, and hospital collection partnerships.
Broad incumbents
- SRL Diagnostics: One of India's largest diagnostic chains (owned by Agilus Diagnostics) operating 400+ labs. Competes with LifeCell Diagnostics on advanced testing, oncology, and hospital lab management services with deeper brand and corporate hospital contracts.
- Dr. Lal PathLabs: India's largest diagnostic chain with pan-India network of NABL-accredited labs. Competes broadly with LifeCell Diagnostics on routine testing while offering deeper geographic penetration and brand recognition across consumer and hospital channels.
Regional players
- Cells4Life: UK-headquartered cord blood and tissue bank offering multi-tier storage plans globally. Operates as a regional/overseas alternative that some Indian parents may consider for international storage; benchmark competitor on processing technology and pricing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
LifeCell International social profiles
Digital presenceLifeCell International compliance and trust
Trust signalCompliance7 records
LifeCell International financial estimates
Financial estimateRevenue estimate
Valuation estimate
LifeCell International leadership team
Management profileNumber of profiles
Profiles3 records
LifeCell International subsidiaries and ownership
Company hierarchySubsidiaries2 records
LifeCell International funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LifeCell International M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LifeCell International
What does LifeCell International do?
LifeCell International operates a community stem cell banking service that preserves umbilical cord blood stem cells for expectant parents and their families, with subscription-based plans ranging from 1-year to 75-year storage. The company also provides pan-India diagnostic laboratory services (4,000+ tests through LifeCell Diagnostics), placental tissue-derived wound care allograft products (HuPla FLO, HuPla Matrix, HuPla PHMB), B2B hospital lab management services, and the AreoVeda natural skincare brand for mothers and babies.
Is LifeCell International a public or private company?
LifeCell International is a private company. It is classified as venture growth investor backed and is currently operating.
When was LifeCell International founded?
LifeCell International was founded in 2004. It employs 1,001 to 5,000 people.
Where is LifeCell International based?
LifeCell International is headquartered in Chennai, India, in the Asia region.
How does LifeCell International make money?
Five revenue lines are on record. Stem Cell Banking Services are the primary driver. The others are diagnostic/Lab Testing Services, allograft/Biologics Products, skincare Products (AreoVeda) and hospital Lab Management Services.
Who are LifeCell International's main competitors?
Direct peers on record are Mamaearth (Honasa Consumer), Metropolis Healthcare, Thyrocare Technologies, CordLife India, ReeLabs, StemCyte India and CryoSave (now BioSave). Broad incumbents are SRL Diagnostics and Dr. Lal PathLabs. Cells4Life is listed as a regional player.
Does LifeCell International have an API?
No public API is recorded for LifeCell International.
What industry is LifeCell International in?
LifeCell International's product category is Stem Cell Banking. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAABAJ, Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring). Its NAICS code is 621991 and its SIC code is 2836.